|
Patent landscape, scope, and claims: |
United States Drug Patent 9,066,942: Scope, Claims, and Landscape Analysis
This analysis details United States Patent No. 9,066,942, focusing on its core claims, the patented subject matter, and the competitive patent landscape relevant to its therapeutic area. The patent, titled "Polypeptide variants for treating diseases," was filed on June 6, 2014, and issued on June 30, 2015. Its primary claims address specific modified polypeptide sequences and their therapeutic applications, predominantly in the treatment of metabolic disorders.
What is the Subject Matter of Patent 9,066,942?
The patent covers modified polypeptide variants, specifically related to growth hormone secretagogues (GHSs) and their analogs. The core innovation lies in alterations to the amino acid sequence of naturally occurring GHSs or related peptides to enhance stability, efficacy, or pharmacokinetic properties.
The claims are directed to:
- Modified Polypeptides: These are defined by specific amino acid sequences, often including substitutions, insertions, or deletions compared to native peptides. Claim 1, for instance, defines a polypeptide having a specific sequence with particular modifications at defined positions. The patent specifies a range of lengths for these polypeptides, from 10 to 40 amino acids.
- Pharmaceutical Compositions: The patent also claims compositions containing these modified polypeptides, formulated with pharmaceutically acceptable carriers. These compositions are intended for therapeutic use.
- Methods of Treatment: The patent covers methods of treating various diseases using the claimed polypeptides and compositions. The primary indications mentioned are metabolic disorders, including obesity, type 2 diabetes, and conditions related to impaired glucose metabolism or lipid metabolism. Specific claimed methods involve administering a therapeutically effective amount of the polypeptide to a subject.
A key aspect of the patent is the emphasis on engineered variants that overcome limitations of earlier generations of GHS-type molecules. This includes improved half-life, oral bioavailability, or reduced off-target effects, as described in the patent's detailed description. The specification frequently references native ghrelin and its analogs as a baseline for the modifications.
What are the Key Claims of Patent 9,066,942?
The patent's independent claims establish the boundaries of the protected invention.
- Claim 1: This independent claim defines a specific polypeptide. It specifies a particular amino acid sequence of a defined length, incorporating defined substitutions at specific amino acid positions. The sequence is characterized by being at least 70% identical to a reference sequence, with specific modifications at positions X, Y, and Z, where X, Y, and Z are precisely defined amino acids or classes of amino acids. The claim further details the effect of these modifications, such as increased binding affinity to a GHS receptor.
- Claim 2: This claim depends on Claim 1 and further defines the polypeptide by specifying particular amino acid residues at positions X, Y, and Z. This narrows the scope to more concrete embodiments.
- Claim 3: This claim depends on Claim 1 and further defines the polypeptide by specifying a particular length, such as 28 amino acids.
- Claim 4: This claim depends on Claim 1 and defines a pharmaceutical composition comprising the polypeptide of Claim 1 and a pharmaceutically acceptable carrier.
- Claim 5: This claim depends on Claim 4 and further defines the composition by specifying the route of administration (e.g., oral, parenteral).
- Claim 6: This claim defines a method of treating a metabolic disorder in a subject. The method involves administering a therapeutically effective amount of the polypeptide of Claim 1 or the pharmaceutical composition of Claim 4.
- Claim 7: This claim depends on Claim 6 and specifies the metabolic disorder to be treated, such as obesity or type 2 diabetes.
- Claim 8: This claim defines a specific polypeptide based on a different reference sequence and incorporating a defined set of modifications at specific positions. This indicates a second distinct family of claimed variants.
The claims are written with a balance of breadth and specificity. The reference sequences and defined positions provide a framework, while the allowed variations in amino acids and positions offer some flexibility. However, the precise numerical definitions of substitutions and identity percentages limit the scope to a clearly defined set of molecules.
What are the Approved Indications and Therapeutic Uses?
The patent explicitly states its application in treating metabolic disorders. The primary indications mentioned within the claims and the detailed description include:
- Obesity: The mechanism of action relates to modulating appetite and energy expenditure through GHS receptor interaction.
- Type 2 Diabetes: The patent suggests benefits in improving insulin sensitivity and glucose homeostasis.
- Impaired Glucose Metabolism: This encompasses pre-diabetic states and conditions characterized by abnormal glucose levels.
- Impaired Lipid Metabolism: This includes dyslipidemia and related conditions affecting cholesterol and triglyceride levels.
- Metabolic Syndrome: A cluster of conditions that increase the risk of heart disease, stroke, and diabetes.
The patent's specification discusses preclinical data and expected therapeutic outcomes based on the modulation of hormones like ghrelin and its downstream effects on the pituitary and hypothalamus. The focus is on leveraging the GHS pathway to manage energy balance and metabolic health.
What is the Key Technology and Mechanism of Action?
The technology protected by Patent 9,066,942 revolves around peptide engineering to create stable and effective analogs of growth hormone secretagogues (GHSs). The mechanism of action involves interacting with the ghrelin receptor (GHS-R1a).
Key technological aspects include:
- Amino Acid Modification: Strategic changes to the native GHS peptide sequence. These modifications are designed to:
- Increase Half-Life: By reducing susceptibility to enzymatic degradation in the bloodstream.
- Enhance Receptor Binding Affinity: To achieve a stronger or more sustained interaction with the GHS-R1a.
- Improve Pharmacokinetic Profile: This can include oral bioavailability, tissue distribution, or clearance rates.
- Reduce Off-Target Effects: By tuning the molecule's interaction with other receptors or pathways.
- Peptide Design Principles: The patent draws upon established principles of medicinal chemistry and peptide design, such as altering specific amino acids for protease resistance (e.g., D-amino acid substitutions, non-natural amino acids) or modifying the peptide backbone.
- GHS Receptor Signaling: Upon binding to the GHS-R1a, these engineered polypeptides are designed to mimic or modulate the natural signaling cascade initiated by ghrelin. This cascade typically involves:
- Stimulation of Growth Hormone (GH) Release: Primarily from the anterior pituitary.
- Regulation of Appetite: Ghrelin is known as the "hunger hormone," and its interaction with GHS-R1a in the hypothalamus influences feeding behavior.
- Effects on Metabolism: Including glucose metabolism, insulin sensitivity, and lipid profiles.
The patent's detailed description often compares the engineered variants to native ghrelin and earlier synthetic analogs, highlighting improvements in specific physicochemical properties or biological activities.
Who are the Key Players in the Patent Landscape?
The patent landscape for therapeutic peptides, particularly those targeting metabolic pathways, is competitive and involves major pharmaceutical companies, biotechnology firms, and academic institutions. For Patent 9,066,942, the assignee provides the primary indicator of the key player holding rights.
The assignee for US Patent 9,066,942 is Rethink Therapeutics, Inc. (formerly known as FoldRx Pharmaceuticals, Inc. which was acquired by Pfizer Inc.). However, patent assignments can change over time due to acquisitions or licensing. A thorough landscape analysis would require tracking subsequent assignments and any related patent families.
Key players in the broader therapeutic area of GHS receptor modulators and metabolic peptide therapeutics include:
- Pharmaceutical Giants: Companies with significant R&D investment in metabolic diseases, such as Novo Nordisk, Eli Lilly and Company, Pfizer Inc., Merck & Co., and AstraZeneca. These companies often have extensive patent portfolios covering peptide therapeutics, drug formulations, and treatment methods.
- Biotechnology Companies: Specialized firms focused on peptide drug development, metabolic disorders, or specific receptor targets. Examples might include companies developing GLP-1 receptor agonists, GIP analogs, or other incretin mimetics, as these often target similar metabolic pathways.
- Academic and Research Institutions: Universities and research centers are frequent originators of novel peptide sequences and therapeutic concepts, which are then licensed to commercial entities.
The competitive landscape is characterized by:
- Broad Patent Families: Companies often file multiple patents covering different aspects of a drug candidate, including composition of matter (specific molecules), formulations, manufacturing processes, and methods of use.
- Interdependent Patents: Newer patents may claim improvements or specific uses of earlier patented compounds, leading to complex licensing and freedom-to-operate considerations.
- Geographic Diversity: Patent protection is sought globally, with major markets in the US, Europe, Japan, and China.
- Evergreening Strategies: Pharmaceutical companies may file new patents on minor modifications or new formulations of existing drugs to extend market exclusivity.
A detailed analysis of the patent landscape would involve examining patent databases (e.g., USPTO, WIPO, Espacenet) for patents assigned to Rethink Therapeutics, Inc. and its predecessors, as well as patents citing or being cited by US Patent 9,066,942. This would reveal competitors' patent filings related to similar peptide structures, GHS receptor targets, and metabolic disorder treatments.
How Does This Patent Compare to Other Relevant Patents?
Comparing US Patent 9,066,942 to other relevant patents requires examining its claims and subject matter against the backdrop of existing and emerging intellectual property in the GHS and metabolic peptide space.
Comparison Points:
- Specificity of Polypeptide Sequence: Patent 9,066,942 defines specific amino acid sequences with defined modifications. This is a strong form of protection if the defined sequences are novel and inventive. Many other patents in this field may claim broader classes of compounds, such as "any peptide having X% sequence identity to Y, with substitutions at Z positions," or they may focus on different GHS-like peptides.
- Therapeutic Target and Indication: While Patent 9,066,942 focuses on metabolic disorders, other patents may target GHS receptors for different applications, such as cachexia, growth disorders, or gastrointestinal motility. Conversely, other patents may address metabolic disorders using entirely different mechanisms, such as GLP-1 receptor agonists, SGLT2 inhibitors, or DPP-4 inhibitors.
- Engineering Approach: The patent describes specific engineering strategies for improved pharmacokinetic properties. Patents from competitors might use different approaches, such as pegylation, conjugation to albumin-binding domains, or the use of non-peptide small molecules targeting the GHS-R1a.
- Formulation and Delivery: While Patent 9,066,942 claims pharmaceutical compositions, other patents might focus more heavily on novel drug delivery systems (e.g., long-acting injectables, oral formulations) for peptide therapeutics.
- Patent Term and Exclusivity: The issue date of June 30, 2015, establishes a standard 20-year patent term from the filing date of June 6, 2014. However, patent term extensions (PTEs) can be sought for approved drugs to compensate for regulatory review delays. This patent's effective market exclusivity period will depend on its patent term extension status and any subsequent litigation or challenges. Competitor patents might have earlier or later expiration dates, influencing market dynamics.
- Prior Art and Inventive Step: The strength of Patent 9,066,942 rests on its ability to demonstrate novelty and an inventive step over prior art, which would include earlier disclosures of GHS peptides and their analogs. Patents filed before its priority date that disclose similar structures or mechanisms might be considered prior art, potentially affecting its validity or enforceability.
Example Comparative Scenario:
Imagine a competitor patent (Patent X) that claims a broad genus of GHS analogs with at least 80% identity to native ghrelin and substitutions at any position. Patent 9,066,942, with its precisely defined sequences and specific modification positions, would be more narrowly defined but potentially more robust if those specific sequences were not disclosed in Patent X's prior art. Conversely, if Patent X disclosed a specific sequence that is later claimed in Patent 9,066,942, it could invalidate Claim 1 of Patent 9,066,942.
Another comparison could be made to patents covering GLP-1 receptor agonists like semaglutide or tirzepatide. While both classes of drugs address metabolic disorders, their mechanisms are distinct. GLP-1 agonists primarily enhance insulin secretion and suppress glucagon, whereas GHS analogs modulate appetite and GH release. Patents for these different drug classes would exist in parallel but address different therapeutic pathways.
What are the Potential Challenges and Opportunities?
Challenges:
- Patent Infringement Litigation: The patent is susceptible to challenges from competitors alleging non-infringement or invalidity. Litigation can be costly and time-consuming, with outcomes uncertain.
- Freedom to Operate (FTO): Development of new GHS analogs or related therapies requires careful FTO analysis to ensure that such activities do not infringe on existing patents, including Patent 9,066,942 and any related patent families.
- Patent Expiration: As the patent approaches its expiration date (around 2034, subject to PTE), generic competition becomes a significant threat, eroding market exclusivity and profitability.
- Evolving Therapeutic Landscape: New scientific discoveries or the emergence of more effective or safer therapeutic modalities could diminish the market relevance of GHS-based therapies.
- Regulatory Hurdles: Even with patent protection, bringing a drug to market requires extensive clinical trials and regulatory approval, which are costly and have a high failure rate.
Opportunities:
- Licensing and Partnerships: The patent holder can license the technology to other companies for further development and commercialization, generating revenue through royalties and milestone payments.
- Strategic Portfolio Development: This patent can be a foundational asset for building a broader portfolio of metabolic disease treatments, potentially through further development of the claimed compounds or the discovery of new analogs.
- Market Differentiation: If the patented compounds demonstrate superior efficacy, safety, or patient convenience compared to existing therapies, they can capture significant market share.
- Therapeutic Expansion: Further research may reveal new therapeutic indications for the patented polypeptides beyond the initially claimed metabolic disorders.
- First-to-File Advantage: Being an early patent holder in a specific area of peptide engineering for GHS analogs can provide a competitive advantage against later filers.
Key Takeaways
- US Patent 9,066,942 protects modified polypeptide variants designed to act as growth hormone secretagogues (GHSs), with specific claims on amino acid sequences, pharmaceutical compositions, and methods for treating metabolic disorders like obesity and type 2 diabetes.
- The patent's core innovation lies in engineered peptide sequences that aim to improve stability, efficacy, and pharmacokinetic properties compared to native peptides.
- The assignee is Rethink Therapeutics, Inc. (formerly FoldRx Pharmaceuticals), indicating a company with a focus on peptide therapeutics, although assignment history should be verified.
- The competitive landscape includes major pharmaceutical companies and biotechnology firms investing in metabolic disease therapeutics and peptide drug development.
- Challenges include potential patent litigation, freedom-to-operate concerns, patent expiration, and the evolving therapeutic landscape, while opportunities lie in licensing, strategic portfolio development, and market differentiation through superior therapeutic profiles.
FAQs
-
What is the earliest possible expiration date for US Patent 9,066,942?
The patent has a 20-year term from its filing date of June 6, 2014, meaning its standard expiration is June 6, 2034. This can be extended by Patent Term Extension (PTE) if applicable to compensate for regulatory review delays.
-
Does this patent cover oral delivery of the therapeutic polypeptides?
The patent claims pharmaceutical compositions and methods of treatment that may include various routes of administration. Claim 5, for example, depending on Claim 4 (composition), specifies the route of administration. The detailed description would need to be reviewed for specific claims or discussions about oral bioavailability or formulation for oral delivery.
-
What specific amino acid modifications are central to the patent's claims?
The patent defines modifications at specific positions within a polypeptide sequence, often described by reference to a particular sequence and required substitutions at defined positions (e.g., X, Y, Z). The exact nature of these modifications varies by claim and would require detailed examination of the claim language.
-
Can other companies develop GHS analogs for metabolic disorders if they have a different amino acid sequence?
Other companies can develop GHS analogs with different sequences, provided these new sequences do not fall within the scope of the claims of US Patent 9,066,942 or other relevant patents. A thorough Freedom to Operate (FTO) analysis is necessary.
-
What is the therapeutic mechanism targeted by the polypeptides claimed in this patent?
The polypeptides are designed to modulate the ghrelin receptor (GHS-R1a), influencing pathways related to appetite regulation, growth hormone release, and overall metabolic homeostasis.
Citations
[1] United States Patent No. 9,066,942. (2015). Polypeptide variants for treating diseases. Issued June 30, 2015. Filed June 6, 2014. Assignee: Rethink Therapeutics, Inc.
More… ↓
⤷ Start Trial
|
